More noteworthy is that treating MIA PaCa-2 and BxPC-3 cells with the β2-antagonist significantly downregulated the NNK increased HIF-1α expression along with the concomitant inhibition of cell proliferation and invasion, and HIF-1α overexpression abolished β2-antagonist-induced effects on pancreatic cancer. The gene discussed is HIF1A; the disease is familial pancreatic carcinoma.